Novel goose parvovirus vp1 protein truncated gene, recombinant duck plague virus and application

By constructing a recombinant duck plague virus with a truncated gene of the novel goose parvovirus VP1 protein inserted into it, a bivalent live vector vaccine was prepared, which solved the prevention and control problem of duck short-beaked dwarf syndrome caused by the novel goose parvovirus and achieved safe and effective immune protection.

CN122168636APending Publication Date: 2026-06-09ZHEJIANG ACADEMY OF AGRICULTURE SCIENCES
View PDF 2 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
ZHEJIANG ACADEMY OF AGRICULTURE SCIENCES
Filing Date
2024-12-06
Publication Date
2026-06-09

AI Technical Summary

Technical Problem

Existing technologies are insufficient to effectively control duck short-beaked dwarf syndrome caused by a novel goose parvovirus. Traditional vaccines are costly, pose safety risks, and have unstable immunization effects. Furthermore, there is a lack of safe and effective vaccine preparation methods.

Method used

A recombinant duck plague virus was constructed, and a truncated gene of the novel goose parvovirus VP1 protein was inserted to prepare a novel goose parvovirus-duck plague virus bivalent live vector vaccine. By immunizing ducks, the viral shedding was shortened, thus achieving effective immune protection.

Benefits of technology

Recombinant duck plague virus vaccine can shorten the shedding time of novel goose parvovirus in ducks, improve the immune effect, reduce economic losses, and increase the qualified rate of ducks for slaughter.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122168636A_ABST
    Figure CN122168636A_ABST
Patent Text Reader

Abstract

The application discloses a novel goose parvovirus VP1 protein truncated body gene, a recombinant duck plague virus and application. The novel goose parvovirus VP1 protein truncated body gene has a nucleotide sequence shown as SEQ ID No. 1. The recombinant duck plague virus has the novel goose parvovirus VP1 protein truncated body gene inserted into the genome of the recombinant duck plague virus. The application obtains a novel goose parvovirus VP1 protein truncated body gene, inserts the truncated body into the genome of the recombinant duck plague virus, and obtains the recombinant duck plague virus, and the rsVP1-Cre immune group shortens the NGPV discharge in the duck body, and the duck body immune rsVP1-Cre is helpful to the NGPV discharge. It is shown that the recombinant duck plague virus with the VP1 protein truncated body gene inserted can be used for preparation of a novel goose parvovirus-duck plague virus double live vector vaccine.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Recombinant duck plague virus of expressing duck tembusu virus E protein as well as construction method and application of recombinant duck plague virus

    CN105039268A

  • Truncated gene of duck Tembusu virus E protein and recombinant duck plaque virus, and construction method and application thereof

    CN107312782A